Lerodalcibep Shows Promise for HeFH in Phase 3 LIBerate-HeFH Trial
Data from the first of 3 phase 3 trials examing lerodalcibep provide insight into the effects of the once-monthly PCSK9 inhibitor in patients with heterozygous familial hypercholesterolemia.
Hcplive Derick Raal Derick Raal Evan Stein European Society Of Cardiology Carbohydrate Lipid Metabolism Research Unit Faculty Of Health Sciences
Source: hcplive.com